Ustekinumab trough concentrations predict clinical remission in perianal fistulizing crohn’s disease: a real-world retrospective cohort study
UST achieves 74.2% fistula clinical remission at 52 weeks in PFCD, with trough concentrations at 16/20 weeks predictive of clinical remission. These findings support the use of therapeutic drug monitoring(TDM) to optimize clinical outcomes.
Authors
- Bolin Yang (ORCID: https://orcid.org/0000-0002-2474-4085)
- Xiaoyu Liu (ORCID: https://orcid.org/0000-0002-0763-0182)
- Dongmei Luo
- Yuxia Gong
- Yi Jiang (ORCID: https://orcid.org/0009-0004-1777-3891)
- Hao Wang (ORCID: https://orcid.org/0000-0002-9971-1237)
- Jun Geng (ORCID: https://orcid.org/0000-0003-1348-2355)
- Yunfei Gu (ORCID: https://orcid.org/0000-0003-2979-0934)
- Jingjing Wang (ORCID: https://orcid.org/0000-0001-7603-2795)
- Yuehua Yan (ORCID: https://orcid.org/0009-0004-7219-805X)
- Huixian Huang
Institutions
- Nanjing University of Chinese Medicine (CN)
- Jiangsu Province Hospital (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1186/s12876-025-04323-x
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Government of Jiangsu Province